ClinConnect ClinConnect Logo
Search / Trial NCT01841008

Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NICE · Apr 23, 2013

Trial Information

Current as of April 25, 2025

Terminated

Keywords

[C17.800.621]

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \> 18 years
  • Non-segmental vitiligo repigmented more than 75% with treatment (any type of treatment is accepted: NB-UVB, PUVA, lamp or excimer laser at 308 nm, topical steroids, topical tacrolimus, graft). The total area treated plates during maintenance treatment should not exceed 10% of the total body surface area.
  • Affiliation to the Social Security
  • Informed consent signed by the patient
  • Exclusion Criteria:
  • Segmental Vitiligo
  • Pregnant or breastfeeding women (pregnancy test will be conducted); effective contraception will be maintained for the duration of the study.
  • Allergy to macrolide derivatives.
  • Exposure to UV or concomitant exposure to the sun without protective shield.
  • Concomitant immunosuppressive therapy or oral corticosteroids for topical (on the vitiligo lesions) or systemic

Trial Officials

PASSERON Thierry, Pu-Ph

Principal Investigator

CHU de Nice - Service de Dermatologie - Hôpital de l'Archet - 151 Route de saint-antoine de ginestière 06200 Nice

About Centre Hospitalier Universitaire De Nice

The Centre Hospitalier Universitaire (CHU) de Nice is a leading academic medical center located in Nice, France, dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHU de Nice is committed to enhancing patient care by conducting rigorous studies that explore new therapies and treatment modalities across various medical disciplines. With a focus on collaboration, the center integrates cutting-edge technology and interdisciplinary expertise to ensure the highest standards of research integrity and patient safety. CHU de Nice plays a vital role in the development of evidence-based medicine, contributing significantly to the global medical community.

Locations

Nice, Alpes Maritimes, France

Bordeaux, Gironde, France

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials